Literature DB >> 23034317

Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease.

Charlotte U Andersen1, Søren Mellemkjær, Jens Erik Nielsen-Kudsk, Elisabeth Bendstrup, Ulf Simonsen, Ole Hilberg.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is an important complication to interstitial lung disease (ILD). The aim of the present study was to investigate the relation of NT-proBNP, fibrin D-dimer, troponin-T, uric acid and exhaled nitric oxide (NO) to the presence of PH and mortality in ILD.
METHODS: In a previously described cohort of 212 ILD patients of whom 29 had PH, levels of the above mentioned biomarkers were analyzed as routine tests.
RESULTS: A value of NT-proBNP below 95 ng/l had a negative predictive value for PH of 99% (95% CI: 94-100). Values of troponin-T were higher in patients with PH (median (inter quartile range) = 9 (9-20) vs. 9(9-10) ng/l), and the odds ratio (OR) for PH was increased in patients with abnormal levels of uric acid (OR (95% CI) = 3.1(1.1-8.8)). NT-proBNP and troponin-T values above the 50(th) percentile, and uric acid and fibrin D-dimer values above the 90th percentile were each associated with increased mortality.
CONCLUSIONS: A value of NT-proBNP below 95 ng/l may be used as a rule-out test for PH in ILD, while an abnormal value of uric acid is a risk factor for PH. NT-proBNP, troponin-T, uric acid and fibrin D-dimer have prognostic value in ILD patients, while exhaled levels of NO do not seem to predict PH or mortality.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034317     DOI: 10.1016/j.rmed.2012.09.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

2.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

3.  [Clinical significance of hypersensitive C-reactive protein, fribrinogen and D-dimmer in connective tissue disease-related interstitial lung disease].

Authors:  Si-Jie Yuan; Hai-Ting Xie; Zhong-Li Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

4.  Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study.

Authors:  Nilay Orak Akbay; Zuleyha Bingol; Esen Kiyan; Ekrem Bilal Karaayvaz; Ahmet Kaya Bilge; Halim Issever; Gulfer Okumus
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

5.  NT-proBNP <95 ng/l can exclude pulmonary hypertension on echocardiography at diagnostic workup in patients with interstitial lung disease.

Authors:  Charlotte Andersen; Søren Mellemkjær; Ole Hilberg; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2016-07-29

Review 6.  Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Magdalena Rysz-Górzynska; Anna Gluba-Brzózka; Amirhossein Sahebkar; Maria-Corina Serban; Dimitri P Mikhailidis; Sorin Ursoniu; Peter P Toth; Vera Bittner; Gerald F Watts; Gregory Y H Lip; Jacek Rysz; Alberico L Catapano; Maciej Banach
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

Review 7.  Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Authors:  Tiago M Alfaro; Carlos Robalo Cordeiro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

8.  Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection.

Authors:  Raj Parikh; Ippokratis Konstantinidis; David M O'Sullivan; Harrison W Farber
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.